The US indapamide market is estimated to grow significantly during the forecast period. The significant prevalence of hypertension along with the CVD and high healthcare expenditure is primarily contributing to the market growth in the region. According to the Center for Medicare and Medicaid Services, in 2018, the US national healthcare expenditure was around $3.6 trillion showing a 4.4% increase in healthcare expenditure up from 3.9% in 2017. It is further expected to reach $6.0 trillion by 2027. The US has the highest healthcare spending across the globe. CVD and strokes accounted for 14% of the total healthcare expenditure. Around 1 in 19 mortalities in the US were due to stroke in the country in 2017 causing more than 146,000 mortalities. In the US, the per capita healthcare expenditure per person in 2018 was around $10,800. Thus, high expenditure is likely to support the growth of the market.
Get Free Sample link @ https://www.omrglobal.com/request-sample/us-indapamide-market
The US indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
A full report of US Indapamide Market available @ https://www.omrglobal.com/industry-reports/us-indapamide-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
US Indapamide Market by Product
- 25 MG
- 5 MG
US Indapamide Market by Application
- High Blood Pressure
- Heart Failure
- Others
Company Profiles
- ANI Pharmaceuticals, Inc.
- Apotex Inc.
- Glenmark Pharmaceuticals Ltd.
- Krka Group
- Mylan N.V.
- Preferred Pharmaceuticals, Inc.
- Sanis Health Inc.
- Sanofi S.A.
- Teva Pharmaceuticals Industries Ltd.
- Servier Group
The Report Covers
- Comprehensive research methodology of the US indapamide market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the US indapamide market.
- Insights about market determinants which are stimulating the US indapamide market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/us-indapamide-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
